Introduction
============

Natural killer (NK)/T-cell lymphoma (NTCL) is a distinct clinicopathologic disease, as defined by the World Health Organization (WHO), displaying very aggressive features of lymphoproliferative diseases \[[@b1-crt-2017-051]\]. Although long-term outcomes with conventional combination chemotherapy have been unsatisfactory in the past \[[@b2-crt-2017-051],[@b3-crt-2017-051]\], recent phase II studies have demonstrated the efficacy of L-asparaginase‒based combination chemotherapy with a backbone of ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) in newly diagnosed stage IV or refractory NTCL \[[@b4-crt-2017-051]-[@b6-crt-2017-051]\].

In Korea, three preparations of asparaginase for treating NTCL are available: native *Escherichia coli* L-asparaginase (L-ASP), namely pegylated *E. coli* asparaginase (PEG-ASP), and Erwinia-derived asparaginase. Generally, the *E. coli*‒derived enzyme is used as front-line therapy, and the *Erwinia*-derived preparation is only reserved for patients who develop hypersensitivity reactions \[[@b7-crt-2017-051],[@b8-crt-2017-051]\]. However, native *E. coli* L-ASP is associated with notable side-effects including hypersensitivity, pancreatitis, and thrombosis \[[@b7-crt-2017-051]-[@b12-crt-2017-051]\]. Hypersensitivity to native *E. coli* L-ASP has resulted in a poorer outcome due to inactivation of asparaginase by antibodies \[[@b13-crt-2017-051]\]. PEG-ASP is potentially less immunogenic than native *E. coli* L-ASP and has a longer half-life, which allows one injection of PEG-ASP to replace multiple injections of native *E. coli* L-ASP \[[@b14-crt-2017-051],[@b15-crt-2017-051]\]. PEG-ASP is now being used as the initial asparaginase preparation in some pediatric acute lymphoblastic leukemia (ALL) treatment regimens after randomized trials have confirmed that it has similar toxicity and efficacy to native *E. coli* L-ASP \[[@b16-crt-2017-051],[@b17-crt-2017-051]\].

Although PEG-ASP has been used as the initial asparaginase preparation in some prospective NTCL clinical trials in China \[[@b18-crt-2017-051],[@b19-crt-2017-051]\] and the pharmacokinetics of each asparaginase preparation have been well-defined in many reports \[[@b20-crt-2017-051]-[@b22-crt-2017-051]\], there are no studies that compare the ASP-related toxicity of PEG-ASP with native *E. coli* L-ASP in the NTCL population. In addition, the length of hospital stay and number of visits to the emergency room (ER) after chemotherapy with each drug preparation have not been clearly reported. The aim of this study was to compare ASP-related toxicity between two asparaginase preparations, namely native *E. coli* L-ASP and PEG-ASP, in combination with IMEP in NTCL.

Materials and Methods
=====================

1. Patients
-----------

A total of 41 patients who were treated with IMEP plus native *E. coli* L-ASP or PEG-ASP for NTCL between January 2013 and March 2016 at Seoul National University Hospital were retrospectively identified. The inclusion criteria were AS follows: (1) pathologically confirmed NTCL according to the WHO criteria \[[@b1-crt-2017-051],[@b23-crt-2017-051]\]; (2) treatment with IMEP plus native *E. coli* L-ASP or PEG-ASP; and (3) eligibility for ASP-related toxicity evaluation after chemotherapy. Clinical demographics including age, sex, B symptoms, Eastern Cooperative Oncology Group performance status (ECOG PS), serum lactate dehydrogenase level, Ann Arbor stage, number of extranodal sites, International Prognostic Index (IPI) score, Korean Prognostic Index (KPI) score, Prognostic Index of Natural Killer Lymphoma (PINK) score, Prognostic Index of Natural Killer Lymphoma-Epstein-Barr virus (PINK/E) score, and previous lines of chemotherapy, were recorded \[[@b24-crt-2017-051],[@b25-crt-2017-051]\].

2. Treatment
------------

All patients received chemotherapy consisting of IMEP, plus native *E. coli* L-ASP or PEG-ASP. The choice of asparaginase preparation in combination with the IMEP regimen was made by the primary physician. The conventional IMEP regimen consists of ifosfamide at a dose of 1.5 g/m^2^, administered intravenously on days 1 to 3 with adequate hydration of 2 L of half-saline per day and mesna to prevent hemorrhagic cystitis; methotrexate at a dose of 30 mg/m^2^, given intravenously on day 4; and etoposide at a dose of 100 mg/m^2^, administered intravenously on days 1 to 3. In the IMEP plus L-ASP group, prednisolone was given at a dose of 50 mg/m^2^ orally on days 1 to 5. In the IMEP plus PEG-ASP group, dexamethasone was given at a dose of 20 mg intravenously on days 1 to 4. Patients received either intravenous native *E. coli* L-ASP 6,000 IU/m^2^ (capped at 10,000 IU) on days 1, 3, 5, 7, 9, and 11 or intravenous PEG-ASP 2,500 IU/m^2^ (capped at 3,750 IU) on day 1 of each cycle. Each cycle of chemotherapy was given every 3 weeks. For patients with stage I/II NTCL, up to three-to-four cycles of treatment were planned, followed by involved-field radiotherapy (IFRT). For patients with stage III/IV NTCL, up to six cycles of treatment were planned. Treatment was continued until disease progression, unacceptable toxicities, or refusal by the patient. To minimize allergic reactions with native *E. coli* L-ASP, all patients were allergy tested at 1 hour prior to receiving native *E. coli* L-ASP at our institution. In cases of positive skin test and hypersensitivity to L-ASP, patients were required to receive native *E. coli* L-ASP under a desensitization protocol.

3. Asparaginase-related toxicity assessment
-------------------------------------------

Toxicity was assessed according to the Common Terminology Criteria for Adverse Events, ver. 3.0. Asparaginase-related toxicities were defined as toxicities that are caused by asparagine depletion and have been commonly reported in clinical trials in combination with IMEP in NTCL \[[@b4-crt-2017-051]-[@b6-crt-2017-051]\]; these included hepatotoxicity (measured by elevated levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), and total bilirubin (t-bil), hypoalbuminemia, hypofibrinogenemia; all grades), hyperglycemia, hypertriglycemia (all grades), pancreatitis (grade 2 or worse), and allergy (all grades, including anaphylaxis). For patients with no history of diabetes mellitus, hyperglycemia was defined as two or more random blood glucose levels higher than 200 mg/dL. For patients with underlying diabetes mellitus, prescription of new hyperglycemia medication or increase in the dose of hyperglycemia medication after starting treatment with IMEP plus native *E. coli* L-ASP or PEG-ASP was considered as an event of hyperglycemia. Hematological toxicities were not included because these toxicities are routinely encountered at diagnosis and during treatment of NTCL. Toxicity was continually monitored for one cycle up to the subsequent cycle of chemotherapy, initiation of a different chemotherapy regimen due to disease progression, or death.

To compare toxicity patterns between the two groups after the first cycle and during chemotherapy, we observed changes in AST, ALT, ALP, t-bil, and albumin between day 1 of the first cycle and 3 weeks after the last cycle of chemotherapy. We calculated absolute change and percentage change in laboratory values (ΔAST, ΔALT, ΔALP, Δt-bil, and Δalbumin).

4. Length of hospital stay and clinical outcomes
------------------------------------------------

The length of hospital stay and number of visits to the ER were compared after each cycle of IMEP plus native *E. coli* L-ASP or PEG-ASP. Clinical outcomes were assessed by physical examination, otolaryngologic examination, computed tomography scans, and positron emission tomography (PET) scans, using the response criteria for lymphoma \[[@b26-crt-2017-051]\].

Briefly, complete response (CR) was defined as disappearance of all evidence of disease with no PET-positive lesions. Partial response (PR) was defined as at least 50% decrease in the sum of the product of the diameters of up to six dominant masses, and no increase in size of other nodes. Progressive disease (PD) was defined as any new lesion or at least 50% increase of any single previously identified node and stable disease is defined as failure to attain the criteria needed for a CR or PR, but doe s not fulfill those of PD. Responses were assessed every two cycles during chemotherapy and best responses to chemotherapy were used in the analysis. Overall survival (OS) and progression-free survival (PFS) were calculated as the time from the date of the first administration of IMEP plus native *E. coli* L-ASP or PEG-ASP up to the date of either death or the final follow-up visit, and to the date of disease progression, respectively, confirmed by the response assessment of lymphoma \[[@b26-crt-2017-051]\].

5. Statistical analysis
-----------------------

Clinical variables were compared between the two groups using the Pearson chi-square or Fisher exact tests for categorical variables, and by the Wilcoxon rank-sum test for continuous variables. We used multivariable logistic regression to adjust for baseline differences when comparing asparaginase-related toxicity, where necessary. Percentage changes in laboratory values (ΔAST, ΔALT, ΔALP, Δt-bil, Δalbumin, and Δfibrinogen) before and after chemotherapy were compared between the two groups using the Wilcoxon signed rank test. Survival curves were derived by the Kaplan-Meier method and compared using a log-rank test. A significance level of \< 0.05 was used for p-values. All analyses were performed using SPSS ver. 22.0 (IBM Corp., Armonk, NY) and STATA ver. 12 (StataCorp LP, College Station, TX).

6. Ethics
---------

This study was approved by the Institutional Review Board of Seoul National University Hospital (H-1508-177-702), and was conducted in accordance with the precepts established by the Declaration of Helsinki.

Results
=======

1. Patients' characteristics and treatments
-------------------------------------------

A total of 22 patients received IMEP plus native *E. coli* L-ASP for 77 cycles, and 19 patients received IMEP plus PEG-ASP for 54 cycles. All clinical demographics were similar between the L-ASP and PEG-ASP groups. The median age was 58.8 years in the L-ASP group and 55.9 years in the PEG-ASP group. A total of 11 (50.0%) patients in the L-ASP group and nine (47.4%) patients in the PEG-ASP group had Ann Arbor stage III/IV NTCL. Patients in each group were well balanced according to the PINK and PINK/E model. A total of 15 (68.2%) and 14 (73.7%) NTCL patients received IMEP plus L-ASP or IMEP plus PEG-ASP, respectively, as a first-line therapy. Baseline laboratory values were similar between the two groups ([Table 1](#t1-crt-2017-051){ref-type="table"}).

In L-ASP group, seven patients with stage I/II and five patients with stage III/IV completed the planned chemotherapy. Ten patients discontinued chemotherapy due to death (n=2), disease progression (n=5), and unacceptable toxicities (n=3). In PEG-ASP group, seven patients with stage I/II and five patients with stage III/IV completed the planned chemotherapy. Seven patients discontinued chemotherapy due to death (n=1), unacceptable toxicities (n=5), and refusal by the patient (n=1). Eight patients in L-ASP group and seven patients in PEG-ASP group received sequential IFRT at median doses of 40.5 Gy and 42.0 Gy, respectively. Three patients in L-ASP group and two patients in PEG-ASP group received autologous stem-cell transplantation and allogenic stem-cell transplantation as consolidation, respectively.

2. Asparaginase-related toxicity assessment
-------------------------------------------

The asparaginase-related toxicity of the current study is summarized in [Table 2](#t2-crt-2017-051){ref-type="table"}. Hepatotoxicity was the most frequent asparaginase-related toxicity in both the L-ASP and PEG-ASP groups. There were no significant differences between the levels of AST, ALT, ALP and t-bil, or hypoalbuminemia between the two groups. However, more patients in the L-ASP group experienced hypofibrinogenemia compared to the PEG-ASP group (86.4% vs. 36.8%, p=0.001).

More patients in the L-ASP group experienced an allergic reaction, although the difference was not significant. In our study, three patients (13.6%) taking L-ASP had a positive skin test prior to receiving native *E. coli* L-ASP. All three patients received native *E. coli* L-ASP under a desensitization protocol, and two patients completed all subsequent cycles of native *E. coli* L-ASP under the desensitization protocol without allergic toxicities. However, one patient experienced a grade 3 allergic reaction despite the desensitization protocol and, therefore, switched to Erwinia-derived asparaginase. A grade 3 allergic reaction occurred in one patient on L-ASP despite a negative skin test result, and this patient completed all subsequent cycles of IMEP plus L-ASP under a desensitization protocol. One patient treated with IMEP plus PEG-ASP experienced an asparaginase-related grade 3 allergic reaction and, as a result, discontinued this drug from subsequent cycles of chemotherapy.

There was no significant difference in the frequency of grade 3 or above asparaginase-related toxicity between the two groups. Two patients experienced grade 4 asparaginase-related toxicity; one patient developed grade 4 hypertriglyceridemia after six cycles of IMEP plus L-ASP, and another patient experienced grade 4 hypofibrinogenemia after two cycles of IMEP plus PEG-ASP. These latter two adverse events were not life-threatening and soon resolved after chemotherapy was completed. There were no treatment-related deaths in this study.

Upon analysis of the asparaginase-related toxicity per cycle of chemotherapy, the frequency of toxicity in each group was found to be comparable. However, hyperglycemia and allergy occurred more frequently in the L-ASP group (p=0.045 and p=0.005, respectively). Frequency of grade 3 or above asparaginase-related toxicity per cycle of chemotherapy did not show any significant difference between the two groups ([S1 Table](#SD1-crt-2017-051){ref-type="supplementary-material"}).

The level of changes in hepatic enzymes, bilirubin, and albumin between native *E. coli* L-ASP and PEG-ASP after chemotherapy were similar in two groups. Patients who received IMEP plus L-ASP and PEG-ASP displayed significantly elevated levels of AST, ALT, ALP, and t-bil and decreased level of albumin after chemotherapy compared to before chemotherapy (p \< 0.05) ([Fig. 1](#f1-crt-2017-051){ref-type="fig"}). When we compared the percent change of AST, ALT, ALP, t-bil, and albumin before and after chemotherapy, level of changes were similar between two groups ([Fig. 2](#f2-crt-2017-051){ref-type="fig"}). However the toxicity pattern after the first cycle of chemotherapy was significantly different. Only the patients who received IMEP plus PEG-ASP showed significantly elevated levels of AST, ALT, ALP, and t-bil after one cycle of chemotherapy compared to day 1 (AST, p=0.024; ALT, p=0.033; ALP, p \< 0.001; and t-bil, p \< 0.001). Although the level of albumin significantly decreased in both groups, the slope of change was more significant in the PEG-ASP group (in both groups p \< 0.001) ([S2 Fig.](#SD2-crt-2017-051){ref-type="supplementary-material"}). When we compared the percentage change of AST, ALT, ALP, t-bil, and albumin between the two groups on day 1 of the first cycle and 3 weeks after the first cycle, patients in the PEG-ASP group displayed significantly elevated levels of AST, ALT, and t-bil compared to the L-ASP group (AST, p=0.036; ALT, p=0.034; and t-bil, p \< 0.001) ([S3 Fig.](#SD3-crt-2017-051){ref-type="supplementary-material"}).

3. Length of hospital stay and dose profile of chemotherapy
-----------------------------------------------------------

We compared the length of hospital stay and number of visits to the ER between the L-ASP and PEG-ASP groups after each cycle of chemotherapy. The number of ER visits was not significantly different between the two groups. Five patients received 13 cycles of IMEP plus PEG-ASP at an outpatient clinic leading to significantly shorter hospital stays in PEG-ASP group compared to L-ASP group (median, 4.0 days vs. 6.0 days; p=0.002) ([Table 3](#t3-crt-2017-051){ref-type="table"}).

In order to investigate the effect of asparaginase-related toxicity on the dose profile of chemotherapy, we analyzed the number of cycles with reduced doses, the amount of dose reduction, and the number of completed injections of L-ASP or PEG-ASP according to the planned treatment course. The number of cycles with reduced doses and the amount of dose reduction did not show any significant difference between the two groups. Native *E. coli* L-ASP was given according to the planned treatment course in only 62 cycles (80.5%), whereas PEG-ASP was given according to the planned treatment course in all cycles (p \< 0.001). Native *E.coli* L-ASP was incompletely injected in 15 cycles due to toxicities and intolerance ([S4 Table](#SD4-crt-2017-051){ref-type="supplementary-material"}).

4. Clinical outcomes and survival analysis
------------------------------------------

Thirty-nine patients were eligible for response evaluation. The PEG-ASP group showed a tendency towards better clinical outcome compared to the L-ASP group in NTCL. Five patients (23.8%) in the L-ASP group and four patients (22.2%) in the PEG-ASP group achieved a PR after chemotherapy. The number of patients who achieved a CR was different between the two groups, although the difference was not statistically significant: 10 patients (47.6%) in the L-ASP group and 14 patients (77.8%) in the PEG-ASP group. Although five patients (23.8%) in L-ASP group showed disease progression, none in PEG-ASP group showed disease progression during the follow-up period ([Table 4](#t4-crt-2017-051){ref-type="table"}).

After a median follow up of 23.3 months (range, 1.3 to 46.7 months), median PFS and OS were not significantly different between the two groups regardless of the Ann Arbor stage in patients who received the first-line IMEP plus L-ASP or PEG-ASP ([S5 Fig.](#SD5-crt-2017-051){ref-type="supplementary-material"}). High IPI, KPI, and PINK/E scores reduced survivals in NTCL patients ([S6 Fig.](#SD6-crt-2017-051){ref-type="supplementary-material"}).

Discussion
==========

Our results show that native *E. coli* L-ASP and PEG-ASP showed a similar frequency of asparaginase-related toxicity in combination with IMEP in NTCL. Hypofibrinogenemia was the only asparaginase-related toxicity that differed in frequency between the L-ASP and the PEG-ASP groups. However, the toxicity patterns were significantly different in the two groups. After the first cycle of IMEP plus PEG-ASP, patients displayed significantly elevated levels of AST, ALT, ALP, and t-bil whereas the level of albumin decreased significantly. Patients who received IMEP plus PEG-ASP seemed to have a significantly shorter length of hospital stay compared to IMEP plus L-ASP. IMEP plus PEG-ASP also showed a trend towards better clinical outcomes compared to IMEP plus L-ASP in NTCL.

PEG-ASP was first approved in 1994 for use in ALL patients who had developed hypersensitivity to native *E. coli* L-ASP \[[@b27-crt-2017-051]\]. PEG-ASP is potentially less immunogenic than native *E. coli* L-ASP and has a longer half-life, which allows one injection of PEG-ASP to replace multiple injections of native *E. coli* L-ASP. However, PEG-ASP is also associated with significantly higher median nadir serum asparaginase activity levels compared to native *E. coli* L-ASP \[[@b16-crt-2017-051]\]. Since toxicities such as hyperglycemia and thrombosis are caused by asparagine depletion \[[@b28-crt-2017-051],[@b29-crt-2017-051]\], there have been concerns that asparaginase-related toxicity could occur more frequently with PEG-ASP, and that toxicities may last longer due to the longer half-life of this preparation. In our study, the frequency of asparaginase-related toxicity was not significantly different between the L-ASP and PEG-ASP groups, except for hypofibrinogenemia, which occurred more frequently in the L-ASP group. Our study results were similar to the results of a phase 3 trial that compared native *E. coli* L-ASP with PEG-ASP in childhood ALL as a part of the postinduction regimen \[[@b16-crt-2017-051]\].

Although the changes in levels of hepatic enzymes, bilirubin, and albumin before and after chemotherapy were similar between two groups, the pattern of asparaginase-related toxicity was significantly different between the L-ASP and PEG-ASP groups after the first cycle. Patients displayed significantly elevated levels of AST, ALT, ALP, and t-bil, and a decrease in albumin levels after the first cycle of IMEP plus PEG-ASP. If a patient experienced significant hepatotoxicity due to increased AST, ALT, ALP, and t-bil levels or the decrease in albumin and fibrinogen, the subsequent cycle of chemotherapy would be delayed until the patient recovered from the toxicities. This could be an important point to consider when choosing the preparation of asparaginase because sustained asparagine depletion is more affected by dose intervals than by the dose per se, due to the anti-leukemic effect, which is dependent on the duration of asparagine depletion \[[@b15-crt-2017-051]\]. However, the frequency of asparaginase-related toxicities in a total of 131 cycles between L-ASP and PEG-ASP did not show a significant difference except hyperglycemia and allergy which occurred more frequently in L-ASP group.

In our study, some patients were able to receive IMEP plus PEG-ASP at an outpatient clinic which enabled PEG-ASP to significantly shorten the length of hospital stay, without increasing the number of visits to the ER, as compared to L-ASP. However, it was easier to adjust the schedule and dose of native *E. coli* L-ASP when toxicity occurred, as native *E. coli* L-ASP was given on multiple days, whereas PEG-ASP was only given on day 1 of each cycle. In our study, native *E. coli* L-ASP was given in combination with IMEP, according to the planned treatment course in only 62 cycles, whereas PEG-ASP was given in combination with IMEP according to the planned treatment course in all cycles. A tendency towards more favorable outcome was shown in IMEP plus PEG-ASP, compared to IMEP plus L-ASP, with regard to the CR rate.

The current study had several limitations. Firstly, it only included a small number of patients, which makes it difficult to apply the results of this study to a general NTCL population. Secondly, it was a retrospective study and the choice of asparaginase preparation was made by the primary physician. This could have created selection bias in the study results. However, when considering that the incidence of NTCL only accounts for 6.3% of all non-Hodgkin's lymphoma in Korea, it is not easy to conduct a prospective trial with an adequate number of patients. Moreover, since the two groups of NTCL patients had similar baseline clinical characteristics and received the same IMEP regimen, the difference in toxicity was mostly dependent on the asparaginase preparation. Despite these limitations, this is the first study to report that the toxicity patterns of IMEP plus L-ASP and IMEP plus PEG-ASP are different after the first cycle of chemotherapy. Moreover, because reports of asparaginase-related toxicities of L-ASP compared with PEG-ASP in NTCL populations are lacking, the results of the current study are highly valuable. Lastly, the pharmacoeconomic implications of the two drugs, such as length of hospital stay, is clearly shown in the current study.

In conclusion, the frequency of asparaginase-related toxicity did not differ between the L-ASP and PEG-ASP groups in NTCL patients, except for hypofibrinogenemia, which occurred more frequently in patients taking L-ASP. The level of change in AST, ALT, ALP, t-bil, and albumin after chemotherapy was also similar between the two groups. IMEP plus PEG-ASP is more convenient than IMEP plus L-ASP for patients, because it can be given at an outpatient clinic which seemed to significantly shorten the length of hospital stay without increasing the number of visits to the ER. IMEP plus PEG-ASP also showed a tendency towards favorable clinical outcomes in terms of CR rate. Therefore, PEG-ASP is effective to a similar extent, and no more toxic than native *E. coli* L-ASP when used as a part of chemotherapy regimen with IMEP in NTCL, and is also associated with shorter hospital stays. Based on the results of this current study, IMEP plus PEG-ASP might be feasible as a front-line treatment of NTCL.
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![Comparison of liver function tests between before chemotherapy (pre) and maximum values after chemotherapy (post). Each dot represents pre and post aspartate aminotransferase (AST) (A), alanine aminotransferase (ALT) (B), alkaline phosphatase (ALP) (C), total bilirubin (t-bil) (D), and albumin (E) levels. The red line represents the change in median pre and post values. Pre and post values were compared within each group using the Wilcoxon signed rank test. L-ASP, L-asparaginase; PEG, pegylated.](crt-2017-051f1){#f1-crt-2017-051}
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###### 

Baseline patient characteristics

                                                                                   IMEP+L (n=22)          IMEP+P (n=19)         p-value
  -------------------------------------------------------------------------------- ---------------------- --------------------- ---------
  **Age (yr)**                                                                                                                  
   \< 60                                                                           12 (54.5)              13 (68.4)             0.364
   ≥ 60                                                                            10 (45.5)              6 (31.6)              
   Median (75% CI)                                                                 58.8 (44.4-68.8)       55.9 (49.8-63.6)      0.896
  **Sex**                                                                                                                       
   Male                                                                            12 (54.5)              8 (42.1)              0.427
   Female                                                                          10 (45.5)              11 (57.9)             
  **Presentation**                                                                                                              
   UAT                                                                             19 (86.4)              14 (73.7)             0.436
   Not UAT                                                                         3 (13.6)               5 (26.3)              
  **B symptoms**                                                                                                                
   No                                                                              15 (68.2)              17 (89.5)             0.140
   Yes                                                                             7 (31.8)               2 (10.5)              
  **Ann Arbor stage**                                                                                                           
   I-II                                                                            11 (50.0)              10 (52.6)             0.867
   III-IV                                                                          11 (50.0)              9 (47.4)              
  **LDH level**                                                                                                                 
   Normal                                                                          11 (50.0)              13 (68.4)             0.233
   Elevated                                                                        11 (50.0)              6 (31.6)              
  **No. of extranodal sites**                                                                                                   
   0-1                                                                             17 (77.3)              16 (84.2)             0.703
   ≥ 2                                                                             5 (22.7)               3 (15.8)              
  **ECOG PS**                                                                                                                   
   0-1                                                                             20 (90.9)              16 (84.2)             0.649
   ≥ 2                                                                             2 (9.1)                3 (15.8)              
  **IPI score**                                                                                                                 
   0-1                                                                             11 (50.0)              10 (52.6)             0.300
   2                                                                               4 (18.2)               7 (36.8)              
   3                                                                               5 (22.7)               1 (5.3)               
   4-5                                                                             2 (9.1)                1 (5.3)               
  **KPI score**                                                                                                                 
   1                                                                               4                      2                     0.006
   2                                                                               7                      6                     
   3                                                                               1                      9                     
   4                                                                               10                     2                     
  **PINK**                                                                                                                      
   Low                                                                             4                      4                     0.917
   Intermediate                                                                    13                     10                    
   High                                                                            5                      5                     
  **PINK/E**                                                                                                                    
   Low                                                                             5                      4                     0.977
   Intermediate                                                                    12                     11                    
   High                                                                            5                      4                     
  **Previous chemotherapy**                                                                                                     
   0                                                                               15 (68.2)              14 (73.7)             0.634
   1-2                                                                             6 (27.3)               5 (26.3)              
   3                                                                               1 (4.5)                0                     
  **AST, median (75% CI)**                                                         33.50 (21.75-110.25)   22.0 (17.0-49.0)      0.169
  **ALT, median (75% CI)**                                                         41.50 (19.50-62.75)    20.0 (13.0-47.0)      0.089
  **ALP, median (75% CI)**                                                         62.50 (52.25-132.25)   94.0 (79.0-133.0)     0.075
  **t-bil, median (75% CI)**                                                       0.65 (0.40-1.00)       0.5 (0.4-0.7)         0.323
  **Albumin, median (75% CI)**                                                     3.65 (3.175-4.15)      3.8 (3.1-4.2)         0.733
  **Fibrinogen, median (75% CI)^[a)](#tfn1-crt-2017-051){ref-type="table-fn"}^**   295.0 (214.5-392)      321.0 (169.0-397.0)   0.959

IMEP+L/P, ifosfamide, mesna, etoposide, prednisolone+L-asparaginase/peg-asparaginase; CI, confidence interval; UAT, upper aerodigestive tract; LDH, lactate dehydrogenase; ECOG PS, Eastern Cooperative Oncology Group performance status; IPI, International Prognostic Index; KPI, Korean Prognostic Index; PINK, Prognostic Index of Natural Killer Lymphoma; PINK/E, PINK-Epstein-Barr virus; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; t-bil, total bilirubin.

Evaluated in 27 patients.

###### 

Asparaginase-related toxicity per patient

                                                   IMEP+L (n=22)   IMEP+P (n=19)   p-value
  ------------------------------------------------ --------------- --------------- ---------
  **Asparaginase-related toxicity (all grades)**                                   
   AST elevation                                   10 (45.5)       9 (47.4)        0.902
   ALT elevation                                   11 (50.0)       12 (63.2)       0.397
   ALP elevation                                   8 (36.4)        11 (57.9)       0.168
   t-bil elevation                                 13 (59.1)       8 (42.1)        0.278
   Hypoalbuminemia                                 16 (72.7)       13 (68.4)       0.763
   Hypofibrinogenemia                              19 (86.4)       7 (36.8)        0.001
   Hyperglycemia                                   5 (22.7)        1 (5.3)         0.112
   Hypertriglycemia                                6 (27.3)        4 (21.1)        0.727
   Pancreatitis                                    1 (4.5)         2 (10.5)        0.588
   Allergy                                         7 (31.8)        3 (15.8)        0.366
  **Asparaginase-related toxicity (≥ grades 3)**                                   
   AST elevation                                   3 (13.6)        2 (10.5)        \> 0.99
   ALT elevation                                   1 (4.5)         2 (10.5)        0.588
   ALP elevation                                   1 (4.5)         0               \> 0.99
   t-bil elevation                                 2 (9.1)         0               0.490
   Hypoalbuminemia                                 1 (4.5)         1 (5.3)         \> 0.99
   Hypofibrinogenemia                              3 (13.6)        3 (15.8)        \> 0.99
   Allergy                                         2 (9.1)         1 (5.3)         0.485

IMEP+L/P, ifosfamide, mesna, etoposide, prednisolone+L-asparaginase/peg-asparaginase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; t-bil, total bilirubin.

###### 

Length of hospital stay and number of ER visits

                                   IMEP+L (77 cycles)   IMEP+P (54 cycles)   p-value
  -------------------------------- -------------------- -------------------- ---------
  Hospital stay, median (75% CI)   6.0 (4.0-13.0)       4.0 (2.25-7.25)      0.002
  ER visit, n (%)                  3 (3.9)              6 (11.1)             0.160

ER, emergency room; IMEP+L/P, ifosfamide, mesna, etoposide, prednisolone+L-asparaginase/peg-asparaginase; CI, confidence interval.

###### 

Clinical outcomes of IMEP plus native *Escherichia coli* L-ASP and PEG-ASP

  Response assessment   IMEP+L (n=21)   IMEP+P (n=18)   p-value
  --------------------- --------------- --------------- ---------
  PR                    5 (23.8)        4 (22.2)        \> 0.99
  CR                    10 (47.6)       14 (77.8)       0.098
  PD                    5 (23.8)        0               0.050
  SD                    1 (4.8)         0               \> 0.99

Values are presented as number (%). IMEP, ifosfamide, mesna, etoposide, prednisolone; L-ASP, L-asparaginase; PEG-ASP, pegylated asparaginase; IMEP+L/P, ifosfamide, mesna, etoposide, prednisolone+L-asparaginase/peg-asparaginase; PR, partial remission; CR, complete remission; PD, progressive disease; SD, stable disease.

[^1]: Hyun Jee Kim and Chan-Young Ock contributed equally to this work.
